Curcumin Liposomal Eye Drops Sterilization via Vitamin E-TPGS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current curcumin formulations face challenges with poor bioavailability and solubility, particularly in ophthalmic applications, as they are difficult to sterilize and maintain stability, especially when using surfactants which can be toxic to ocular tissues.
Innovation Solution
A liposomal formulation with curcumin and vitamin E-TPGS, where the weight ratio of vitamin E-TPGS to curcumin is 1:1, is developed, allowing for sterilization by 0.2 micron filtration and maintaining antioxidant and anti-inflammatory effects, while being below the cytotoxic threshold for ocular use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is used in ophthalmic formulations, then anti-inflammatory benefits are provided, but sterilization by filtration is difficult due to poor solubility
Solution Approach 1:
The patent uses Vitamin E-TPGS as an intermediary substance to solubilize curcumin in the ophthalmic formulation. Vitamin E-TPGS acts as a mediator that enables curcumin to be dissolved in water-based solutions, thereby allowing the formulation to be sterilized by filtration through 0.2 micron filters while maintaining the therapeutic benefits of curcumin.
Solution Approach 2:
The invention creates a composite formulation combining curcumin with Vitamin E-TPGS and phospholipids to form liposomes. This composite material approach allows curcumin to be encapsulated in a delivery system that is both soluble and sterilizable, resolving the contradiction between maintaining curcumin's therapeutic properties and achieving sterilization capability.
2Quantity of substance
If surfactants are used to improve curcumin solubility, then bioavailability is enhanced, but cytotoxicity to ocular tissues increases
Solution Approach 1:
The patent changes the chemical parameters by using Vitamin E-TPGS instead of conventional surfactants. This substitution maintains the solubilization function needed for curcumin bioavailability while eliminating the cytotoxic effects associated with traditional surfactants, thus resolving the contradiction between enhanced bioavailability and reduced ocular toxicity.
Solution Approach 2:
The formulation applies local quality by using phospholipid-based liposomes that are biocompatible with ocular tissues. The liposomal structure provides a localized delivery system that enhances curcumin solubility and bioavailability at the site of application without introducing systemically toxic surfactants into the ocular environment.
3Stability of the object's composition
If high concentration of Vitamin E-TPGS is used to solubilize curcumin, then solubility is improved, but ocular cytotoxicity increases
Solution Approach 1:
The patent optimizes the concentration parameter of Vitamin E-TPGS to a specific range (0.025-0.5%) that achieves adequate solubilization of curcumin while remaining below the cytotoxic threshold for ocular tissues. This parameter optimization resolves the contradiction between maintaining solubility and avoiding toxicity.
Solution Approach 2:
The formulation uses a partial amount of Vitamin E-TPGS (enough to solubilize curcumin but not excessive) combined with phospholipid liposomes to achieve the solubilization function. This partial action approach provides sufficient solubility enhancement while staying within safe concentration limits for ocular application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively conveys curcumin to ocular tissues, providing anti-inflammatory benefits and reducing inflammatory phenomena, with improved stability and bioavailability, making it suitable for topical treatment of dry eye syndrome without the need for preservatives.
Implementation Method 1
the liposomal formulation includes the use of vitamin E - D-α-tocopherol polyethylene glycol (TPGS) with the dual purpose of promoting the formation and stability of the liposomes and simultaneously providing a strong antioxidant effect
Implementation Method 2
A liposomal formulation with curcumin and vitamin E-TPGS, where the weight ratio of vitamin E-TPGS to curcumin is 1:1, is developed, allowing for sterilization by 0.2 micron filtration and maintaining antioxidant and anti-inflammatory effects
Implementation Method 3
which is sterilizable by filtration on 0.2 um filter
Data Source
Figure 1
Figure 2
AI summary
A liposomal formulation with curcumin, where the amount of curcumin varies from 0.025% to 0.050% by weight of the total weight, is stable over time, even without preservatives and is sterilizable by filtration on 0.2 μm filter, so as to be usable as eye drops. Eye drops based on this liposomal formulation with curcumin additionally include the use of vitamin E-D-α-tocopherol polyethylene glycol (TPGS) with the dual purpose of promoting the formation and stability of liposomes and simultaneously providing a strong antioxidant effect. The vitamin E-TGPS is present in an amount between 0.025 and 0.5% by weight with respect to the final composition. A method for preparing these eye drops and the use thereof for the topical treatment of dry eye syndrome is described.